NCT02804308

Brief Summary

Breast cancer is a multifactorial disease affecting women, and one of the treatments for its healing and survival is hormone therapy. Aromatase inhibitors are third-generation drugs that promote lower chance of metastasis, but their side effects include the loss of bone mineral density and increased fat percentage. In this way, the Combined Training (combined resistance and endurance training) may be an interesting strategy to minimize the side effects of aromatase inhibitors, providing better quality of life, survival and changes in body composition.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
83

participants targeted

Target at P25-P50 for not_applicable breast-cancer

Timeline
Completed

Started Aug 2015

Shorter than P25 for not_applicable breast-cancer

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2015

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2016

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

June 10, 2016

Completed
7 days until next milestone

First Posted

Study publicly available on registry

June 17, 2016

Completed
Last Updated

June 17, 2016

Status Verified

March 1, 2015

Enrollment Period

10 months

First QC Date

June 10, 2016

Last Update Submit

June 16, 2016

Conditions

Keywords

Combined TrainingBreast CancerBody CompositionPostmenopausal WomenAromatase InhibitorsQuality of life

Outcome Measures

Primary Outcomes (1)

  • Chance from Body composition at 9 months assessment by bone densitometry (Dual-energy x-ray absorptiometry), using the equipment model GE Lunar - DPX-NT

    At baseline, 3, 6 and 9 months timepoint

Secondary Outcomes (14)

  • Quality of life assessed via the questionnaire EORTC (European Organization for Research and Treatment of Cancer Quality of Life Questionnarie).

    At baseline, 3, 6 and 9 months timepoint

  • Bone mineral density (total, spine and femur) in these participants by bone densitometry (Dual-energy x-ray absorptiometry), using the equipment model GE Lunar - DPX-NT.

    At baseline, 3, 6 and 9 months timepoint

  • Serum levels of glucose in these participants measured by enzymatic colorimetric kit processed in Autohumalyzer A5

    At baseline, 3, 6 and 9 months timepoint

  • Serum levels of C-reactive protein (CRP) in these participants measured by enzymatic colorimetric kit processed in Autohumalyzer A5

    At baseline, 3, 6 and 9 months timepoint

  • Serum levels of total cholesterol and fractions in these participants measured by enzymatic colorimetric kit processed in Autohumalyzer A5.

    At baseline, 3, 6 and 9 months timepoint

  • +9 more secondary outcomes

Study Arms (2)

Group Control with breast cancer and without breast cancer

NO INTERVENTION

Stretching exercises, lasting 40 minutes each session, 2 times a week for nine months

Combined Training with breast cancer and without breast cancer

EXPERIMENTAL

Combined Training: 36 weeks duration, 3 times a week on nonconsecutive days. The combined training program lasts 70 minutes per session, with 40 minutes of resistance training and 30 minutes of aerobic training.

Behavioral: Combined Training

Interventions

Combined Training with breast cancer and without breast cancer

Eligibility Criteria

Age50 Years - 80 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Postmenopausal, defined by the absence of periods for the past 12 months;
  • Breast cancer diagnosis stages 1 to 3;
  • The adjuvant treatment for breast cancer and / or neoadjuvant aromatase inhibitors
  • No abnormalities on screening physical or any health problems that contraindicate study participation;
  • No contraindications for treadmill testing or entry into a training program, including any of the following:
  • Myocardial infarction within the past 6 months
  • Pulmonary edema
  • Myocarditis Pericarditis
  • Unstable angina
  • Pulmonary embolism or deep vein thrombosis
  • Uncontrolled hypertension (i.e., blood pressure \> 200/100 mm Hg)
  • Uncontrolled arrhythmia
  • No significant mental illness
  • Have medical certificate to perform exercise testing and participate in combined training
  • Able to answer Questionnaires
  • +3 more criteria

You may not qualify if:

  • Accumulating 3 unexcused absences or 4 consecutive unexcused absences during the month.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Felipe J, Viezel J, Reis AD, da Costa Barros EA, de Paulo TRS, Neves LM, Junior IFF. Relationship of different intensities of physical activity and quality of life in postmenopausal women. Health Qual Life Outcomes. 2020 May 6;18(1):123. doi: 10.1186/s12955-020-01377-1.

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Ismael F Freitas Junior, Doctor

    UPECLIN HC FM Botucatu Unesp

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
TREATMENT
Intervention Model
FACTORIAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
masters degree

Study Record Dates

First Submitted

June 10, 2016

First Posted

June 17, 2016

Study Start

August 1, 2015

Primary Completion

June 1, 2016

Study Completion

June 1, 2016

Last Updated

June 17, 2016

Record last verified: 2015-03